A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Advanced Solid Tumors · Ewing Sarcoma · Hepatocellular Carcinoma (HCC) · Biliary Tract Cancer (BTC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The City of Hope National Medical Center, Duarte, California, United States
Contact: Study coordinator (Kathryn Zurcher) · kzurcher@coh.org · 626-218-3029
Contact: Principal Investigator (Daneng Li)
Hoag Memorial Hospital, Newport Beach, California, United States
Contact: Study coordinator (Holland Orndorff) · Holland.Orndorff@hoag.org · 949-764-7110
Contact: Principal Investigator (Alain Mita)
Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Kristina Goodwin) · kgoodwin@mgh.harvard.edu · 617-643-6256
Contact: Principal Investigator (Gregory Cote)
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Suzanne George) · Suzanne_George@dfci.harvard.edu · 877-338-7425
Contact: Principal Investigator (Suzanne George, MD)
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Pri Wartanian) · wartant@mskcc.org · 210-685-2159
Contact: Principal Investigator (Robert Maki)
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Kofi Effa Ababio) · KEAbabio@mdanderson.org · 346-725-3989
Contact: Principal Investigator (Jordi Rodon Ahnert)

View source on ClinicalTrials.gov Contact study team (email)